Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Eganelisib · IPI-549

Small molecule · Inhibitor of phosphoinositide-3-kinase gamma (PIK3CG) · developed by Arcus Biosciences

Phase 1 Most advanced trial (none active)
RCUS Developer
1 Registered trials

What is Eganelisib?

Eganelisib (IPI-549) is an orally bioavailable, highly selective small molecule inhibitor of the gamma isoform of phosphoinositide-3 kinase (PI3K-gamma). It acts by blocking PI3K-gamma-mediated signaling in tumor cells and immune cells that express the isoform, and is studied in triple-negative breast cancer and ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IPI-549
Drug type
Small molecule
Targets
phosphoinositide-3-kinase gamma (PIK3CG)
Mechanism
Inhibitor of phosphoinositide-3-kinase gamma (PIK3CG)
Pathways
PI3K/Akt signaling, tumor cell proliferation and survival, anti-tumor immune response modulation
Therapy area
Oncology
Developer
Arcus Biosciences, Inc. (RCUS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
FOF5155FMZ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03719326 Phase 1 TNBC - Triple-Negative Breast Cancer Completed RCUS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian CancerTNBC - Triple-Negative Breast Cancer

More from Arcus Biosciences

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RCUS page.

Follow RCUS, the company behind Eganelisib

See RCUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RCUS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.